Kedor, C., Listing, J., Zernicke, J., Weiß, A., Behrens, F., Blank, N., Henes, J. C., Kekow, J., Rubbert-Roth, A., Schulze-Koops, H., Seipelt, E., Specker, C., & Feist, E. (2020). canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Annals of the rheumatic diseases, 79(8), 1090–1097. http://access.bl.uk/ark:/81055/vdc_100127573128.0x000062